Strategic collaboration with Evotec
C4X Discovery has announced a new strategic collaboration with Evotec, which builds on a previous agreement (January 2015) to develop new small molecule drugs across a range of targets, therapeutic areas and stages of development. The agreement is a risk-shared multi-target programme. This is a positive development and builds on the recent fund-raising (£5.0m before expenses via a placing of 4.9m new shares, at 102p) as it enables outputs from its drug discovery engine and its preclinical pipeline to progress.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.